Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for beauty industry professionals · Tuesday, September 26, 2023 · 657,795,384 Articles · 3+ Million Readers

Lanadelumab Market is anticipated to exhibit a CAGR of 7.6% from 2023 to 2031 | Growth Plus Reports

/EIN News/ -- Newark, New Castle, USA, May 25, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global lanadelumab market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 7.6% by 2031.

Analysis of the global market for lanadelumab indicates that the revenue share is likely to rise significantly during the forecast period. The pharmaceutical medicine Lanadelumab is a member of the monoclonal antibody subclass of drugs. Hereditary angioedema (HAE), a rare genetic condition characterized by recurrent swelling in diverse body areas, is prevented by it in patients.

Key Takeaways: 

  • The rising prevalence of hereditary angioedema is driving the market revenue share.
  • The National Center for Biotechnology Information stated that hereditary angioedema affects around 1 in 10,000 to 1 in 50,000 people worldwide.
  • With dosage intervals of two and four weeks, lanadelumab had an average annual cost of $533,988 and $266,994, respectively. 

Request a Sample Copy of the Research Report:

                                               Lanadelumab Market Scope

Report Attribute Details
CAGR 7.6%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Age Group and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Lanadelumab Market: 

  • In February 2023, Takeda said that the FDA had accepted the supplementary biologics license application (sBLA) for the extended use of TAKHZYRO (lanadelumab-flyo) for treatment to prevent attacks of hereditary angioedema (HAE) in pediatric patients between the ages of 2 and 12 years old.
  • In February 2023, Garadacimab (CSL312)'s pivotal placebo-controlled Phase 3 VANGUARD clinical study findings were provided by CSL. Investigational first-in-class monoclonal antibody garadacimab was created by CSL as a long-term preventive therapy for individuals with hereditary angioedema (HAE).

Competitive Landscape

The company operating in the global market for lanadelumab is: 

  • Takeda Pharmaceutical Company Limited 

Market Drivers and Restraints: 

The global lanadelumab market revenue is driven as it has shown in clinical studies to be highly effective at preventing bouts of hereditary angioedema. Furthermore, other hereditary angioedema preventive medications normally demand more frequent administration, whereas lanadelumab's dose frequency permits fewer frequent injections. This ease might result in greater patient satisfaction and adherence, leading to larger market revenue growth.

However, due to high expenses and some potential adverse effects, the lanadelumab market revenue growth is expected to be restrained. 

Request for Customization –

Market Segmentation: 

  • Based on age group, the global lanadelumab market is segmented into adult and pediatric. 

Segmentation By Age Group

The adult segment dominates the global lanadelumab market with the largest revenue share based on age group. Typically, hereditary angioedema appears in youth or maturity. So, the majority of people with Hereditary angioedema who need Lanadelumab therapy are adults. 

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global lanadelumab market. This large share of revenue is attributed to the high prevalence of Hereditary angioedema, advanced healthcare infrastructure, well-established healthcare systems, specialized clinics, and research facilities. 

Report Coverage 

Growth Plus Reports carried out extensive market research on the lanadelumab market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Adult 
    2. Pediatric


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • 'Business Profile' of Key Players

Schedule a call with our analyst:

Visit our report store at -

Browse more latest healthcare reports:

Knee Arthrodesis Implants Market by Product Type (Standard Implants, Customized Implants), Technique (Long Intramedullary Nail, Short Intramedullary Nail), Implantation Technique (Cemented Implantation), End User (Hospitals & Clinics, Emergency Service Centers) – Global Outlook & Forecast 2023-2031

Oncology Imaging Software Market by Indication (Breast Cancer, Lung Cancer), Imaging Technique (CT Scan, MRI), Mode of Delivery (On-cloud, On-premise) – Global Outlook & Forecast 2023-2031

Acute Kidney Injuries Market by Type of Injuries (Pre-renal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injuries, Post-renal Acute Kidney Injuries), Treatment (Drug Therapy, Dialysis) - Global Outlook and Forecast 2023-2031

Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

Manan Sethi
                    Director, Market Insights
                    256 Chapman Road
                    STE 105-4, Newark,
                    New Castle - 19702, USA
                    Phone no: +1 888 550 5009

Primary Logo

Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release